OMED

OncoMed Pharmaceuticals, Inc.
OMED

Overview Fund Activity
Delisted

OMED was delisted on the 22nd of April, 2019.

Back to rankings

66 hedge funds and large institutions have $61M invested in OncoMed Pharmaceuticals, Inc. in 2018 Q1 according to their latest regulatory filings, with 10 funds opening new positions, 18 increasing their positions, 18 reducing their positions, and 13 closing their positions.

Holders
66
Holders Change
-3
Holders Change %
-4.35%
% of All Funds
1.51%
Holding in Top 10
–
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-100%
% of All Funds
–
New
10
Increased
18
Reduced
18
Closed
13
Calls
$2K
Puts
–
Net Calls
+$2K
Net Calls Change
-$1K

Top Buyers

1
Renaissance Technologies
1
Renaissance Technologies
New York
$2.22M
2
Susquehanna International Group
2
Susquehanna International Group
Pennsylvania
$282K
3
BC
3
Birchview Capital
Vermont
$314K
4
SIM
4
Spark Investment Management
New York
$365K
5
Acadian Asset Management
5
Acadian Asset Management
Massachusetts
$181K

Top Sellers

1
Ameriprise
1
Ameriprise
Minnesota
$968K
2
ASP
2
Adams Street Partners
Illinois
$0
3
Millennium Management
3
Millennium Management
New York
$740K
4
ECM
4
Endurant Capital Management
California
$0
5
PP
5
PDT Partners
New York
$0
Name Market Value Shares Shares
Change 		Shares
Change %
WAM
76
Wealthspire Advisors (Maryland)
Maryland
– – -34 Closed
MIM
77
Monashee Investment Management
Massachusetts
– – – –
Citigroup
78
Citigroup
New York
$0 100 – –
VFA
79
Valeo Financial Advisors
Indiana
$0 50 +50 New
TRCT
80
Tower Research Capital (TRC)
New York
$0 79 +79 New
1 2 3
4